8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

424B3 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

EFFECT - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

EFFECT - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

S-8 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

S-8 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

S-1 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

POS AM - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

10-Q - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

CHASKA, Minn., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it will host a virtual investor day on Thursday, November 21, 2024, prior to market open. The event will take place from 8:00 – 9:30 a.m. Eastern Time and be available via webcast. During the event, members of Lifecore's senior management team will discuss the company's business and strategy for growth in the future, among other topics. To listen to the live webcast, or access the archived webcast, please visit the Events & Presentations section of Lifecore's investor web page at: https:

Brings Strong Background in Pharmaceutical Manufacturing Operations and Finance to Help Drive Performance and Productivity Jackie Klecker Named Executive Vice President, Quality and Development Services to Focus on Sustaining Company's Strong Regulatory and Compliance Track Record Personnel Moves Bifurcate Operations and Quality Functions to Align with Company's Growth Strategy and Reflect Natural Evolution of Business CHASKA, Minn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has appointed Thomas Guldager as vice president, operations. An

WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced the appointment of Matthew E. Korenberg as Chief Financial Officer, effective immediately. Mr. Korenberg is a seasoned operational and financial leader with more than 27 years of senior executive experience in biotech companies and healthcare investment banking. Throughout his career, he has focused on capital raising, partnering and licensing deals, acquisitions, as well as overseeing p

-- Recorded Revenues of $24.7 Million for Q1 Fiscal 2025 -- -- Signed Multiple New Business Agreements with New and Existing Customers -- -- More than Doubled Capacity with Installation of 5-Head Isolator Filler; Increased Revenue Generating Potential to Up to $300 Million Annually -- -- Successfully Closed Financing Raising Approx. $24.3 Million, Providing Financial Runway for Current Liquidity Needs and Future Growth -- Conference Call Today at 8:30 a.m. ET CHASKA, Minn., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced its financia

CHASKA, Minn., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced the closing of a $24.3 million private placement ("PIPE") of 5,928,775 shares of its common stock at a price of $4.10 per share. The investing group includes new and existing shareholders, and the company expects to use the proceeds for working capital, operations, and general corporate purposes. "We are very pleased to have the confidence of these new and long-term stockholders, which we believe reflects their support for our new management team, our plan for value creation, and the tremendous opportu

CHASKA, Minn., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it will report financial results for the first quarter of fiscal year 2025 on Friday, October 4, 2024, prior to market open and will host a webcast at 8:30 a.m. Eastern Time. Members of Lifecore's senior management team will discuss financial results for the first quarter and review recent corporate developments. To listen to the live webcast, or access the archived webcast, please visit the Investor Events & Presentations page of Lifecore's website at: https://ir.lifecore.com/events-pre

Multi-Million Dollar Development Agreement Establishes Lifecore as Lindy Biosciences' Preferred CDMO Offers Lifecore Key Access Point into Manufacture and Fill/Finish of Next-Generation Biotherapeutic Formulations with Potential to Deliver Significant Benefits to Patients Worldwide CHASKA, Minn., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that the company has been selected by Lindy Biosciences to provide CDMO services focused on streamlining the formulation process for Lindy Biosciences' innovative microglassification technology and scaling it fo

CHASKA, Minn., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that the company will participate at four upcoming industry events. Details of the company's activities at these events are as follows: Medical Aesthetic Injectable Summit 2024Conference Date/Location: October 4-5, 2024, in Marbella, SpainDetails: Darren Hieber, Lifecore's senior vice president of corporate development and partnerships, will participate in a roundtable discussion and the company will host meetings with existing and prospective customers and partnersRoundtable Topic: Filler

Installation and Qualification Successfully Completed for Closed-System Filler for Pre-Filled Syringes, Vials, and Cartridges Offers State-of-the-Art Speed and Aseptic Isolation Required for Fill/Finish of Latest Sterile Injectable Pharmaceutical and Biopharmaceutical Products Current Capacity More than Doubles with New Filler CHASKA, Minn., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that the company's recently installed high-speed, multi-purpose 5-head isolator filler is GMP-ready and operational. Lifecore is now positioned to offer existing and

CHASKA, Minn., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that Paul Josephs, the Company's president and chief executive officer, and Ryan Lake, the Company's chief financial officer, will be the featured speakers in a fireside chat at the upcoming Craig-Hallum Bioprocessing Conference. The conference will take place virtually on September 19, 2024. Details are as follows: Craig-Hallum Bioprocessing ConferenceDetails: Mr. Josephs and Mr. Lake will participate in a fireside chat and in 1-on-1 meetings Conference Dates: September 19

Craig Hallum initiated coverage of Lifecore Biomedical with a rating of Buy and set a new price target of $8.00

Barrington Research downgraded Lifecore Biomedical from Outperform to Mkt Perform

Stephens downgraded Lifecore Biomedical from Overweight to Equal-Weight and set a new price target of $2.00 from $11.00 previously

-- Recorded Revenues of $24.7 Million for Q1 Fiscal 2025 -- -- Signed Multiple New Business Agreements with New and Existing Customers -- -- More than Doubled Capacity with Installation of 5-Head Isolator Filler; Increased Revenue Generating Potential to Up to $300 Million Annually -- -- Successfully Closed Financing Raising Approx. $24.3 Million, Providing Financial Runway for Current Liquidity Needs and Future Growth -- Conference Call Today at 8:30 a.m. ET CHASKA, Minn., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced its financia

-- Recorded Revenues of $128.3 million for Fiscal 2024; Year-Over-Year Increase of 24.2% ---- High Value Pipeline Continues to Advance Toward Commercialization ---- State-of-the-Art Technology Enhancements to Expand Capacityand New Business Opportunities – Conference Call Tomorrow Morning at 8:30 a.m. ET CHASKA, Minn., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced its financial results for the fourth quarter and full year of fiscal 2024. Highlights from Fiscal 2024: "Operationally, fiscal 2024 was a strong year for the Company as we

Appoints Paul Josephs, an executive with 25 years of CDMO experience as CEO, to succeed current CEO James Hall following his retirement Announces changes to its Board of Directors, appoints new Board Chair CHASKA, Minn., March 20, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that its Board of Directors unanimously approved the conclusion of its review of strategic alternatives that was initiated in March 2023, and, concurrently therewith, announced several strategic updates related to its operations on a stand-alone basis. Board Concludes it

CHASKA, Minn., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), reported results for the fiscal 2023 fourth quarter and full year ended May 28, 2023. CEO COMMENTS: James G. Hall, President and Chief Executive Officer of Lifecore, commented, "We completed a very busy fourth quarter finalizing our transition to a stand-alone life sciences company with the final divestitures of the Curation Foods segment, strong growth in our development portfolio, and the comprehensive strategic refinancing and expanded supply agreement with our key customer Alcon. Our en

CHASKA, Minn., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it will host a conference call to discuss fiscal 2023 fourth quarter financial results. The live webcast can be accessed via Lifecore's website on the Investor Events & Presentations page. The webcast will be available for 30 days. Date: Thursday, August 31, 2023 Time: 7:30 a.m. Central time (8:30 a.m. Eastern time) Direct Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1627193&tp_key=ad066ce9f4 To participate in the conference call via telephone, dial toll-free: 1-877-4

CHASKA, Minn., June 01, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), reported results for the fiscal 2023 third quarter ended February 26, 2023. CEO COMMENTS: James G. Hall, President and Chief Executive Officer of Lifecore, commented, "We took a noteworthy step forward last week with the execution of an enhanced Supply Agreement with a significant, long-term customer, Alcon, as well as completing a comprehensive restructuring of our debt arrangements led by Alcon. These transactions allow the Company to clear the existing Going Concern qualification and create a more sta

CHASKA, Minn., May 22, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it will host a conference call to discuss fiscal 2023 third quarter financial results. The live webcast can be accessed via Lifecore's website on the Investor Events & Presentations page. The webcast will be available for 30 days. Date: Thursday, June 1, 2023 Time: 7:30 a.m. Central time (8:30 a.m. Eastern time) Direct Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1612746&tp_key=4b15043655 To participate in the conference call via telephone, dial toll-free: 1-844-826-30

Company Announces Intention to Explore Strategic AlternativesSigns Term Sheet with Key Customer to Materially Expand Commercial RelationshipExpands Development Pipeline from 24 to 25 Active Projects as of Fiscal Second Quarter-endSubsequently Transitioned Three Projects to Commercialization with FDA Approval in Fiscal Third Quarter, Expanding Commercial Products from 26 to 29 with 14 CustomersFiscal Second Quarter Earnings Call Scheduled for March 17th, 2023 at 8:30 am Eastern Time CHASKA, Minn., March 16, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), reported results for t